Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
|
| gptkbp:activeIngredient |
gptkb:phentermine
|
| gptkbp:availableOn |
gptkb:Australia
gptkb:New_Zealand |
| gptkbp:broadcastOn |
Schedule 4 (Australia)
|
| gptkbp:compatibleWith |
gptkb:United_Kingdom
gptkb:United_States |
| gptkbp:contains |
phentermine resin
|
| gptkbp:contraindication |
gptkb:cardiovascular_disease
pregnancy uncontrolled hypertension |
| gptkbp:drugClass |
anorectic
|
| gptkbp:duration |
short-term
|
| gptkbp:form |
capsule
40 mg 15 mg 30 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Duromine
|
| gptkbp:indication |
obesity
overweight with risk factors |
| gptkbp:manufacturer |
gptkb:iNova_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
appetite suppressant
|
| gptkbp:prescribes |
gptkb:physician
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
increased heart rate
nervousness insomnia dry mouth |
| gptkbp:status |
approved in Australia
approved in New Zealand |
| gptkbp:usedFor |
weight loss
|
| gptkbp:bfsParent |
gptkb:iNova_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|